A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Condition:   HIV Infections Interventions:   Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48);   Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48);   Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48);   Drug: Control PrEP:TDF /FTC once daily (weeks 0-26);   Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors:   MRC/UVRI Uganda Research Unit on Aids;   Imperial College London;   University College, London;   International AIDS Vaccine Initiative;   EuroVacc Foundation;   Medical Research Council, South Africa;   National Institute for Medical Research, Tanzania;   Muhimbili University of Health and Allied Sciences;   Instituto Nacional de Saúde, Mozambique;   Ludwig-Maximilians - University of Munich;   King's College London;   Centre Hospitalier Universitaire Vaudois;   Karolinska Institutet;   CONRAD;   Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials